Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported an insider transaction involving company common stock. On January 20, 2026, she sold 1,581 shares of common stock at $4.86 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, she beneficially owned 84,081 shares of Aura Biosciences common stock, held directly.
Aura Biosciences, Inc. director and President & Chief Executive Officer Elisabet de los Pinos reported an automatic sale of common stock to cover taxes on vesting restricted stock units. On January 20, 2026, she sold 16,928 shares of common stock at a weighted average price of $4.86 per share in multiple trades within a price range of $4.73 to $4.86. After this transaction, she beneficially owned 457,463 shares of Aura Biosciences common stock directly. An additional 127,763 shares were reported as indirectly owned through the Elisabet de los Pinos Revocable Trust, of which she is a trustee. The filing notes that the sales were solely to satisfy tax withholding obligations and were not made at her discretion.
Aura Biosciences, Inc. (AURA) reported an insider tax-related stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 17,109 shares of common stock at a weighted average price of $5.42 per share, with individual sale prices ranging from $5.42 to $5.44. The filing explains that these shares were sold automatically to cover tax withholding obligations tied to the vesting of restricted stock units, and the transactions were not at the officer’s discretion. After these sales, the reporting person beneficially owned 252,685 shares of Aura Biosciences common stock in direct ownership.
Aura Biosciences reported Q3 2025 results, highlighting ongoing late-stage development of bel-sar and continued investment in R&D. Net loss was $26.1 million (basic and diluted loss per share $0.40) on total operating expenses of $27.9 million, driven by research and development of $22.2 million and general and administrative of $5.7 million. Other income was $1.8 million.
Liquidity remained solid with $47.6 million in cash and cash equivalents and $114.3 million in marketable securities as of September 30, 2025. Total assets were $190.0 million and stockholders’ equity was $156.7 million. Shares outstanding were 62,985,569 at quarter-end; 63,503,269 as of November 10, 2025.
Year to date, operating cash use was $64.3 million, offset by financing inflows including the May 2025 follow-on that raised approximately $69.9 million net (common shares, pre-funded warrants, and accompanying warrants) and Q3 activity under the ATM. Management expects current cash and marketable securities to fund operations for at least 12 months from issuance. The Phase 3 CoMpass trial in early choroidal melanoma is ongoing, with enrollment targeted for 2026 and a 15‑month primary endpoint readout planned for Q4 2027.
Aura Biosciences announced its financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1. The company also updated its corporate presentation for investor and analyst meetings, filed as Exhibit 99.2. The press release is furnished under Item 2.02, while the presentation is filed under Item 8.01.
The materials include forward-looking statements covering development timelines, regulatory interactions, manufacturing, commercialization plans, market opportunities, and financing needs. The company notes an expected cash runway into the first half of 2027, with outcomes subject to clinical, regulatory, and operational risks described in its risk factor disclosures.
Aura Biosciences (AURA) filed a Form 4 disclosing that its Senior Vice President, Finance sold 896 shares of common stock at $6.35 on 10/29/2025. According to the filing, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and was automatic, not at the reporting person’s discretion.
Following the transaction, the officer directly holds 85,662 shares of Aura Biosciences common stock.
Aura Biosciences (AURA) Form 4: President and Chief Executive Officer (also a Director) reported an automatic sale tied to tax withholding from RSU vesting. On 10/29/2025, the reporting person sold 9,049 shares of common stock at $6.35 per share (Transaction Code S).
Following the transaction, beneficial ownership was 474,391 shares held directly and 127,763 shares held indirectly through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016. The filing notes the sale was executed solely to satisfy tax obligations and not at the reporting person’s discretion.
Aura Biosciences (AURA) reported an insider transaction by its Chief Technology Officer. On 10/16/2025, the officer sold 12,169 shares of common stock at $6.35 per share. Following the sale, the officer directly held 197,287 shares.
The filing states the sale was executed to cover tax withholding obligations upon the vesting of restricted stock units and was automatic, not at the officer’s discretion.
Aura Biosciences insider filing reports option exercises and a partial sale to cover costs. On 08/18/2025 Senior Vice President, Finance Amy Elazzouzi exercised long-held options to purchase 12,899 shares of Aura common stock across multiple option tranches and exercise prices. Of those shares, 7,722 were sold in multiple transactions at prices ranging from $6.57 to $6.80 (weighted average reported as $6.70). Following the transactions the reporting person beneficially owns 86,558 shares and holds no remaining derivative securities from the exercised options. The filing states the specific exercise prices and vesting/exercise dates for each option tranche.
AURA Form 144 notice reports a proposed sale of 7,722 common shares acquired by stock option exercise on 08/18/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $51,750.53 based on the filing. The filing states there were 62,119,873 shares outstanding at the time. No other securities were reported sold in the prior three months and payment for the acquired shares was in cash.